Chemo Buddies New Wig Shop Offers Free Wigs to Cancer Patients
For many cancer patients, losing their hair is a common side effect of the chemotherapy treatments they receive to remove whatever form of cancer is attacking their body. That loss can be traumatizing for those patients whose bodies and minds are already stressed beyond belief from dealing with their cancer diagnosis. With hair often being a focal point of our appearance and identity, losing it may feel like losing a bit of ourselves. While some may see the loss as a part of the healing process, others may not be comfortable with the idea. For that fall into the second camp, Chemo Buddies is offering a solution.
Note that some links may require registration or subscription.
Over the coming weeks, Ohio will award $1 million to five residents who received a COVID-19 shot, in a lottery aimed at boosting the vaccination rate across the state. (
CBS News)
As of Thursday at 8:00 a.m. EDT, the unofficial U.S. COVID-19 toll reached 32,815,408 cases and 583,690 deaths, increases of 35,994 and 842, respectively, since this time yesterday.
A report from the Independent Panel for Pandemic Preparedness and Response said the world s failures allowed the pandemic to turn into a catastrophic human crisis, and suggested a top-to-bottom overhaul. (
Science)
More than 4,000 people in India have died for the second day in a row, as the country s raging COVID-19 crisis spreads to rural villages. It is a hell out here, said one patient at a hospital in northern Uttar Pradesh. (
In Pivotal Study, KEYTRUDA ® In Combination With Chemotherapy Before Surgery and Continuing as a Single Agent After Surgery Showed Statistically Significant Improvement in EFS Versus Pre-Operative Chemotherapy KEYTRUDA Is the First Anti-PD-1 Therapy to Show a Statistically Significant Improvement in EFS as Neoadjuvant and Adjuvant Therapy for TNBC Merck known as MSD outside the United States and Canada, today … In Pivotal Study, KEYTRUDA ® (pembrolizumab) In Combination With Chemotherapy Before Surgery and Continuing as a Single Agent After Surgery Showed Statistically Significant Improvement in EFS Versus Pre-Operative Chemotherapy KEYTRUDA Is the First Anti-PD-1 Therapy to Show a Statistically Significant Improvement in EFS as Neoadjuvant and Adjuvant Therapy for TNBC
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
First Patient Dosed in Validive
®
Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021
Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery
WILMETTE, Ill., May 13, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2021 financial results and recent business updates.
Recent Business Updates
Validive
Monopar’s Phase 2b/3 VOICE clinical trial of Validive (clonidine HCl mucobuccal tablet) for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC) dosed its first patient in February 2021 and is actively recruiting patients and initiating ad